Abrocitinib is Used for treating adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products. It was first introduced by Pfizer Inc in its drug Cibinqo on Jan 14, 2022.

Abrocitinib Patents

Given below is the list of patents protecting Abrocitinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Cibinqo	US9035074	Pyrrolo[2,3-D]pyrimidine derivatives	Feb 19, 2034	Pfizer
Cibinqo	US9545405	Pyrrolo[2,3-D]pyrimidine derivatives	Feb 19, 2034	Pfizer
Cibinqo	US9549929	Pyrrolo[2,3-D]pyrimidine derivatives	Feb 19, 2034	Pfizer

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳